MedTrace Logo

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

NCT05621005 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2022-11-21

No results posted yet for this study

Summary

Norfloxacin is the most commonly used drug for the prophylaxis against spontaneous bacterial peritonitis (SBP) in patients with liver cirrhosis. Rifaximin, another broad spectrum antibiotic with only trivial absorption from the gut, is used for the treatment of traveler's diarrhea and prevention of hepatic encephalopathy.

Conditions

  • Ascites Infection

Interventions

DRUG

Rifaximin 550 milligram Oral Tablet [XIFAXAN]

Rifaximin was given on dose of 550 milligram every 12 hours orally for at least 3 months

Sponsors & Collaborators

  • Samar Atef Sebaweh Mohammed

    lead OTHER

Principal Investigators

  • Samar A Sebaweh, master · assistant lecturer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2022-07-01
Completion
2022-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05621005 on ClinicalTrials.gov